Psyence Biomedical Ltd. Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence Biomedical Ltd. announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepares for the clinical development of ibogaine for substance use disorders and validates its investment in PsyLabs. This collaboration with PsyLabs is an important step in securing a long-term supply ...

Continue Reading →

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Psyence Biomedical Ltd.

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels ...

Continue Reading →

Ibogaine By David Dardashti Celebrates 5-Year Milestone: Data Confirms Reflection Treatment Significantly Improves Long-Term Success Against Depression

HOLLYWOOD, FL – November 18, 2025 – Ibogaine By David Dardashti, a globally recognized leader in psychedelic-assisted therapies, today announced the five-year anniversary of the strategic integration of its specialized Ibogaine “reflection” treatment protocol. Following five years of meticulous data collection and patient monitoring, the clinic reports significant long-term success improvements for patients utilizing this smaller, follow-up ...

Continue Reading →
Page 27 of 136 «...10202526272829...»
UA-77446339-1